MiRNA-449a is Downregulated in Osteosarcoma and Promotes Cell Apoptosis by Targeting BCL2

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 May 24

PMID 26002578

Citations 25

Authors

Jie Chen

Jinsong Zhou

Xin Chen

Baohui Yang

Dong Wang

Pinglin Yang

Xijing He

Haopeng Li

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence reveals that miR-449a is expressed at a low level in several tumors and cancer cell lines, and acts as a tumor suppressor in several cancers. However, its role in osteosarcoma (OS) is not well understood. In the present study, we found that miR-449a was significantly downregulated in both OS tissues and cell lines. Furthermore, low expression level of miR-449a was correlated with advanced tumor stage, metastasis, and predicted a poor overall survival in OS patients. Additionally, restoration of miR-449a in OS cell lines U2OS and Saos-2 reduced cell viability, promoted cell apoptosis in vitro, and suppressed tumorigenicity in vivo. Moreover, BCL2, an antiapoptotic molecule, was identified to be a direct target of miR-449a, and the proapoptotic function of miR-449a was mainly through targeting BCL2 expression. Taken together, our results demonstrated a tumor-suppressive role of miR-449a in OS progression and suggested a potential therapeutic target for OS.

Citing Articles

Long noncoding RNA DHRS4 antisense RNA 1 suppresses osteosarcoma cell proliferation and promotes apoptosis through a competitive endogenous RNA mechanism.

Tang Z, Li Z, Wu G, Li J, Tan J, Zhu L Sci Rep. 2025; 15(1):2891.

PMID: 39843945 PMC: 11754436. DOI: 10.1038/s41598-025-87246-7.

miR-449a: A Promising Biomarker and Therapeutic Target in Cancer and Other Diseases.

Barati T, Mirzaei Z, Ebrahimi A, Shekari Khaniani M, Mansoori Derakhshan S Cell Biochem Biophys. 2024; 82(3):1629-1650.

PMID: 38809350 DOI: 10.1007/s12013-024-01322-9.

Hedgehog pathway in sarcoma: from preclinical mechanism to clinical application.

Banaszek N, Kurpiewska D, Kozak K, Rutkowski P, Sobczuk P J Cancer Res Clin Oncol. 2023; 149(19):17635-17649.

PMID: 37815662 PMC: 10657326. DOI: 10.1007/s00432-023-05441-3.

Study on the Mechanism of BMSCs in Regulating NF-κB Signal Pathway by Targeting miR-449a to Improve the Inflammatory Response to Peripheral Nerve Injury.

Wang H, Wang F, Wang Y, Li X, Di C, Liang C J Musculoskelet Neuronal Interact. 2022; 22(4):546-561.

PMID: 36458392 PMC: 9716300.

The PI3K/AKT Pathway-The Potential Key Mechanisms of Traditional Chinese Medicine for Stroke.

Gu C, Zhang Q, Li Y, Li R, Feng J, Chen W Front Med (Lausanne). 2022; 9:900809.

PMID: 35712089 PMC: 9194604. DOI: 10.3389/fmed.2022.900809.

References

Weyhenmeyer B, Murphy A, Prehn J, Murphy B . Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Exp Oncol. 2012; 34(3):192-9. View

Lin D, Feng J, Chen W . Bcl-2 and caspase-8 related anoikis resistance in human osteosarcoma MG-63 cells. Cell Biol Int. 2008; 32(10):1199-206. DOI: 10.1016/j.cellbi.2008.07.002. View

Li L, Wu W, Sun D, Xie Z, Ma Y, Zhao Y . miR-449a and CDK6 in gastric carcinoma. Oncol Lett. 2014; 8(4):1533-1538. PMC: 4156198. DOI: 10.3892/ol.2014.2370. View

Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q . MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One. 2013; 8(5):e64759. PMC: 3667122. DOI: 10.1371/journal.pone.0064759. View

Hu J, Fang Y, Cao Y, Qin R, Chen Q . miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci. 2013; 59(2):336-45. DOI: 10.1007/s10620-013-2923-3. View

Botter S, Neri D, Fuchs B . Recent advances in osteosarcoma. Curr Opin Pharmacol. 2014; 16:15-23. DOI: 10.1016/j.coph.2014.02.002. View

Arabi L, Gsponer J, Smida J, Nathrath M, Perrina V, Jundt G . Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma - reasons and consequences. Genes Cancer. 2014; 5(1-2):56-63. PMC: 4063253. DOI: 10.18632/genesandcancer.6. View

Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F . Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol. 2007; 134(2):237-44. DOI: 10.1007/s00432-007-0276-z. View

Hayes J, Peruzzi P, Lawler S . MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460-9. DOI: 10.1016/j.molmed.2014.06.005. View

10.

Noonan E, Place R, Pookot D, Basak S, Whitson J, Hirata H . miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009; 28(14):1714-24. DOI: 10.1038/onc.2009.19. View

11.

Wu P, Chen W, Lee O, Chen C, Huang C, Chen T . The prognosis for patients with osteosarcoma who have received prior manipulative therapy. J Bone Joint Surg Br. 2010; 92(11):1580-5. DOI: 10.1302/0301-620X.92B11.24706. View

12.

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

13.

Ye W, Xue J, Zhang Q, Li F, Zhang W, Chen H . MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A. Oncol Rep. 2014; 32(3):1193-9. DOI: 10.3892/or.2014.3303. View

14.

Chen S, Dai Y, Zhang X, Jin D, Li X, Zhang Y . Increased miR-449a expression in colorectal carcinoma tissues is inversely correlated with serum carcinoembryonic antigen. Oncol Lett. 2014; 7(2):568-572. PMC: 3881925. DOI: 10.3892/ol.2013.1737. View

15.

Kaseta M, Khaldi L, Gomatos I, Tzagarakis G, Alevizos L, Leandros E . Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J Surg Oncol. 2007; 97(3):259-66. DOI: 10.1002/jso.20913. View

16.

Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

17.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

18.

Wei B, Song Y, Zhang Y, Hu M . microRNA-449a functions as a tumor-suppressor in gastric adenocarcinoma by targeting Bcl-2. Oncol Lett. 2013; 6(6):1713-1718. PMC: 3833858. DOI: 10.3892/ol.2013.1609. View

19.

Gill J, Ahluwalia M, Geller D, Gorlick R . New targets and approaches in osteosarcoma. Pharmacol Ther. 2012; 137(1):89-99. DOI: 10.1016/j.pharmthera.2012.09.003. View

20.

Li E, Zhang J, Yuan T, Ma B . MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1. Tumour Biol. 2014; 35(8):7645-50. DOI: 10.1007/s13277-014-2031-9. View